Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRF388 + atezolizumab + bevacizumab
- Development stage
- Unknown
- Lead developer
- Coherus BioSciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SRF388 + atezolizumab + bevacizumab is an investigational **combination immunotherapy and anti-angiogenic regimen** designed for oncology indications, notably being studied for advanced or unresectable hepatocellular carcinoma. SRF388 is a human monoclonal antibody targeting interleukin-27 (IL-27), modulating immune activity within the tumor microenvironment. Atezolizumab is a monoclonal antibody immune checkpoint inhibitor that targets programmed death-ligand 1 (PD-L1) and promotes T cell-mediated anti-tumor immunity. Bevacizumab is a humanized monoclonal antibody that binds vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis and tumor blood vessel growth[2][3][6]. This triple combination strategy is intended to harness immune activation (via SRF388 and atezolizumab) with concurrent tumor vasculature suppression (via bevacizumab).
- Other names
- SRF388 + Tecentriq + Avastin
02
Targets
VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)IL-27p28 (Interleukin-27 subunit alpha)
Beyond the preview
Go deeper on SRF388 + atezolizumab + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRF388 + atezolizumab + bevacizumab.